Coherus Oncology 3Q 2026: Revenue $14.27M, EPS ($0.25) — 10-Q Summary
Coherus Oncology reported 3Q 2026 revenue of $14.27M, up from the prior year, driven by LOQTORZI volume growth. Net loss widened due to higher interest expenses and debt-extinguishment loss. Gross margin was 71%, and R&D expenses declined. The company expects 2026 revenue to exceed 2025, fueled by LOQTORZI growth.
How this was made
The 30-second read
Why it matters
The report shows revenue growth but a widening loss, suggesting short‑term pressure but possible long‑term upside from pipeline focus.
Market read
First‑report earnings for a micro‑cap biotech; likely modest price reaction.
What to watch
Potential upside from upcoming esophageal cancer program and continued LOQTORZI demand.
Background
Coherus Oncology filed its Q3 2026 10‑Q, providing the latest financial and operational metrics.
Ticker impact
Q3 2026 revenue $14.27M and EPS ($0.25) disclosed in the company's 10‑Q filing.
potential downside as investors price in the widened loss and higher expenses
First‑report earnings numbers show a net loss expansion, which typically pressures the stock in the near term.
Market effects
Biotech sector may see modest pressure as small‑cap earnings miss expectations.
Limited to U.S. small‑cap biotech investors.
Minimal; no broader market impact.
Counterpoint
If LOQTORZI volume growth accelerates, the loss may be temporary and the stock could rebound.
Key entities
- companyCoherus Oncology
Biopharmaceutical company developing antibody‑drug conjugates.
